Last updated: 2026-09-05 03:32:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Geron Corp. (GERN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,57, with a market capitalization of $1,02B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,04 to $2,01. This page covers its latest market performance, valuation, price trends and company information.
$1,02B | |
$1,49 | |
$16,80 | |
$0,75 | |
$1,51 | |
10,65M | |
-- | |
-- | |
$2,01 | |
$1,04 | |
-- | |
-- |
Geron Corp. (GERN) last closed at $1,51 as of 2026-09-04 23:49:00, unchanged from the previous close of $1,51.
During the latest regular trading session, GERN traded between $0,75 and $16,80, with a volume of 10,65M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Geron Corp. (GERN) moved from $1,50 to $1,57, representing a gain of 4,87% ($0,07).
The stock traded between $1,47 and $1,59 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 11,86 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 54,9%
GERN is currently trading at $1,57, placing it 54,9% of the way from its 52-week low of $1,04 to its 52-week high of $2,01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Geron Corp. (GERN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.